Category: ACN Newswire

HONG KONG, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2024. Summary of financial results 1H 20241H 2023ChangeTotal Rental Income (HK$ million)1,1151,168- 4.5%Net Property Income (HK$ million)954995- 4.1%Distributable Income (HK$ million)544617 - 11.9% Distribution per unit (HK$)0.08090.0927- 12.7% 30 Jun 202431 Dec 2023ChangeGross Value of Portfolio (HK$ million)61,40662,950- 2.5%Net Asset Value per unit (HK$)7.427.72- 3.9%Gearing Ratio23.1% 22.8%+ 0.3ppOverviewThe high interest rate environment continued to affect the results of the Trust in the first half of 2024. While the total number of tourist arrivals recorded solid growth, the strong local currency dampened consumption and prompted an outflow of domestic travellers. While Langham Place Mall continued to outpace the market in retail sales, the Hong Kong office rental market remained under pressure in light of the supply conditions. Following the successful refinancing, we have ample undrawn committed facilities of HK$4.0 billion to support all the refinancing needs in 2024 and 2025. Amid the challenging macroeconomic environment, distributable income of the Trust decreased by 11.9% to HK$544 million and distribution per unit (“DPU”) declined by 12.7% to HK$0.0809.Three Garden RoadThe occupancy of Three Garden Road remained resilient despite the abundant supply in the market. We observed more enquiries from asset management firms and family offices, and managed to secure some new small-sized tenants during the reporting period. Occupancy stood at 82.3% as at 30 June 2024. Rental income decreased by 9.0% to HK$571 million (2023: HK$627 million) as a result of negative rental reversion in the first half of the year. Langham Place Office TowerLangham Place Office Tower continues to be a lifestyle and wellness hub with lifestyle tenants occupying 69% of the area as at 30 June 2024. As the recovery of mainland medical beauty tourism after the pandemic was slower than expected, some beauty and medical tenants scaled down their operations. Occupancy was 87.1% as at 30 June 2024. Rental income decreased by 4.5% to HK$166 million (2023: HK$174 million).Langham Place MallLangham Place Mall continued to outperform the overall Hong Kong retail market in the reporting period. While Hong Kong retail sales declined by 6.6% in the first half of the year, tenants’ sales of the mall increased by 2.3%. The beauty segment continued to be the growth driver. Occupancy of the mall returned to full occupancy as at 30 June 2024. Rental income improved to HK$378 million (2023: HK$366 million).DistributionDistributable income of the Trust dropped 11.9% to HK$544 million (2023: HK$617 million) and DPU dropped 12.7% to HK$0.0809 (2023: HK$0.0927). Based on the closing unit price of HK$1.57 recorded as at 28 June 2024, the total DPU represented an annualised distribution yield of 10.3%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$61.4 billion as at 30 June 2024, declining by 2.5% from HK$62.9 billion as at 31 December 2023.Sustainability We continue to advance our commitment to sustainable practices across our properties and value chain. Three Garden Road has become Hong Kong’s first existing building conferred with the prestigious “Quadruple Platinum” after achieving the Platinum certification of Leadership in Energy and Environmental Design (LEED) v4.1 and the Platinum certification of WiredScore v3.1. We also continued to strengthen strategic partnerships with tenants and stakeholders. A key initiative was the ESG Week held in this July which featured a diverse range of impactful activities in collaboration with over 20 partners and organisations.OutlookWhile the market generally expects interest rate cuts to start in the second half of 2024, it remains uncertain about the degree of the adjustment. The global economy outlook is also clouded by geopolitical tensions and policy risks. For the office portfolio, we will stay flexible in our leasing strategy to tailor to the requirements of tenants. We will also continue to refine the tenant mix of Langham Place Mall and recruit first-in-Hong Kong brands to strengthen the appeal to both local consumers and tourists. We will stay agile and flexible in response to the market dynamics.Photo 1 - (Left)Ms. Christina Hau, Chief Executive Officer & (Right) Ms. Amy Luk, Investment and Investor Relations DirectorPhoto 2 - Ms. Christina Hau, Chief Executive OfficerAbout Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust was awarded the top five-star rating by the Global Real Estate Sustainability Standard (GRESB) in 2023.Website: www.championreit.comFor press enquiries:Strategic Financial Relations LimitedVicky LeeTel: 2864 4834Email: vicky.lee@sprg.com.hkCynthia Ng Tel: 2114 4952Email: cynthia.ng@sprg.com.hkTheresa OuyangTel: 2864 4848Email: theresa.ouyang@sprg.com.hkWebsite: www.sprg.com.hk Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 20, 2024 - (ACN Newswire via SeaPRwire.com) - SAP announces the grand opening of its "Business AI Experience Center" located at its Hong Kong office. The center aims to showcase the cutting-edge capabilities of integrated Business AI in driving innovation, enhancing efficiency, and boosting business growth through live use cases and success stories. It is designed to guide enterprises from understanding AI to practical implementation, enabling them to achieve digital transformation, and therefore fully explore the unlimited possibilities brought by Business AI.SAP announces the grand opening of its "Business AI Experience Center"located at its Hong Kong office.Esmond Tong, Managing Director of SAP Hong Kong and Macau, said, " With the Business AI Experience Center, SAP aims to create a platform for enterprises and partners to exchange ideas and gain valuable insights that will enhance their agility and creativity. Enterprises can harness SAP's cloud platform to unlock AI's potential and achieve business benefits. With over 50 years of extensive expertise, SAP offers cloud solutions tailored to meet the diverse needs of businesses across industries, regardless of size or development stage, helping them accelerate business growth and development."Esmond Tong, Managing Director of SAP Hong Kong and MacauEarlier this year, SAP announced the full integration of business AI into its cloud portfolios and the gradual rollout of the generative AI copilot, Joule, across the company’s solution portfolio. This initiative is expected to enhance business functions and improve enterprise performance, with Joule managing 80% of the most frequently used tasks. This will make 300 million end users of SAP products 20% more productive, while significantly improving work quality. Meanwhile, SAP is deepening its collaboration with global strategic partners such as Microsoft, AWS, Google Cloud, and NVIDIA to advance the enterprise application of generative AI.The Business AI Experience Center features four live demonstration scenarios. These allow customers to explore innovative applications of SAP Business AI technology being seamlessly integrated into sales, talent management, and marketing processes.- Joule in ERP: Automates and manages sales orders and related processes, significantly enhancing the performance of sales operations.- Just Ask: A conversational AI analysis tool that provides deep sales insights, empowering businesses to make data-driven decisions and drive sales performance.- Talent Writing Assistant: A generative AI tool that helps managers with performance review, talent management, and compensation processes, streamlining HR operations and improving manager effectiveness.- Joule in Customer Experience: Enhances customer engagement and satisfaction through social media posting and exploratory questions, boosting marketing efforts and brand visibility.The "Business AI Experience Center" is now available for visits by appointment. For more information or to schedule a visit, please contact the SAP Hong Kong sales team at +852 2150 2799.Image Download: https://bit.ly/4dP4a7m###About SAPAs a global leader in enterprise applications and business AI, SAP stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. In 2023, SAP was honored for the eighth time with the "Best Workplace in Greater China" award by Great Place to Work. For more information, visit https://www.sap.com/hk‚For media enquiries, please contact:Strategic Public Relations Group (SPRG):Andico Tsuiandico.tsui@sprg.com.hk+852 2114 4346 / 6902 3831Vincent Ipvincent.ip@sprg.com.hk+852 2114 4341 / 5498 9705 Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 20, 2024 - (ACN Newswire via SeaPRwire.com) - DreamFolks, India's largest airport services aggregator, is proud to announce its strategic expansion into the Southeast Asian market. This milestone marks a significant step in DreamFolks' mission to redefine travel experiences on a global scale.Over the past 12 years, DreamFolks has revolutionized the airport services industry in India by offering a comprehensive suite of premium services through its proprietary technology platform. The company dominates the Indian domestic lounge access market for debit and credit card programs, boasting an impressive 90% market share and partnerships with most major banks and card networks in the country. The Company went public in September’22 with listings on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).DreamFolks' success stems from its cutting-edge in-house technology, which empowers banks and card networks to significantly enhance their card value propositions. This technology helps boost sales, drives loyalty and optimizes cost for these financial institutions. This tech-driven approach has been key to DreamFolks' success in India and will continue to fuel its expansion into other geographies.The company's global footprint now extends to over 3000 touchpoints across more than 100 countries and 500+ cities, serving millions of travellers annually. This extensive network positions DreamFolks uniquely to offer unparalleled service to its clients and their customers in the new markets.Building on its success in the Indian market, DreamFolks is now poised to bring its innovative service aggregation model to the Southeast Asian market with services like airport and railway lounges, e-SIM: travel SIM cards, meet and assist services, airport transfers, golf privileges and more to their customers.As part of this expansion, DreamFolks has established a regional office in Singapore, demonstrating its commitment to the market. The company has also bolstered its leadership team by on-boarding, Adib Kangda, Senior Vice President – International Markets, a seasoned professional with extensive knowledge of the local market dynamics.Liberatha Kallat, Chairperson and Managing Director of DreamFolks, commented on the expansion and said, "Our expansion into Southeast Asia marks a significant milestone in DreamFolks' journey. We're not just entering new markets; we're bringing our vision of seamless, technology-driven travel experiences to one of the world's most dynamic regions. This area represents immense opportunities for growth and innovation in the travel sector. With our proven track record in India, we're confident that our unique service aggregation model will resonate strongly with banks, card networks and enterprises across the region. By entering the Southeast Asian market, we will introduce market-first card innovations, and significantly save costs for our clients. Our focus is on delivering tangible benefits for our clients, ensuring they experience enhanced value and efficiency."This expansion is expected to benefit both clients and travellers in the region. By offering its advanced technology solutions, DreamFolks aims to help banks, card networks and enterprises optimise their offerings, enhance customer loyalty, and streamline operations. For travellers, this means access to a broader range of premium services and a more seamless travel experience. This expansion not only marks a new chapter in DreamFolks' journey but also promises to elevate the standards of travel services across the region.About DreamFolksDreamFolks is a leading travel & lifestyle services aggregator and provides an in-house technology platform that allows its clients such as Banks, Card Networks, Airlines, OTAs, and Enterprises to create custom offerings for their end consumers. DreamFolks today manages the lounge and other benefits for most of the top Banks in India and enjoys a market share of over 90% in the domestic lounge access market for India-issued debit and credit programs. The company went public in Sep ’22 with listings on both BSE and NSE and has a global footprint extending to 3,000+ touchpoints in 100+ countries, across the world.For more information, please visit our website (www.dreamfolks.com) or contact our media relations team.Contact Information: dreamfolks@adfactorspr.comNamrata Sharma – Namrata.sharma@adfactorspr.com Copyright 2024 ACN Newswire via SeaPRwire.com.

- Food Expo, Food Expo PRO, Beauty & Wellness Expo, Home Delights Expo and Hong Kong International Tea Fair drew to a successful close today. The five concurrent fairs welcomed some 1,860 exhibitors from 30 countries and regions and attracted over 500,000 visits- Over 90% of local exhibitors accepted electronic payment options for added attendee convenience, and the per capita spending reached HK$1,615; an increase of more than 6% compared to last year- Four new theme days drove local spending, creating a vibrant spending atmosphere- The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM), ended on a high note with 18 renowned speakers discussing the latest issues, including the development of Chinese medicine products in the Greater Bay AreaHONG KONG, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - The HKTDC Food Expo, HKTDC Beauty & Wellness Expo and HKTDC Home Delights Expo, organised by the Hong Kong Trade Development Council (HKTDC), drew to a successful close today, with the total number of visits reaching over 500,000, and an overall spending capita of HK$1,615. The five trade fairs attracted some 1,860 exhibitors from 30 countries and regions and were bustling with visitors amidst a lively spending atmosphere, highlighting the strong appeal and reputation of these annual flagship events.The Food Expo PRO and Hong Kong International Tea Fair also ended on a high note on 17 August. The two trade fairs saw exhibitors and trade buyers from around the world, including some 20,500 buyers from 60 countries and regions. Buyers outside Hong Kong mainly came from Mainland China, Taiwan, Indonesia, Japan, Korea, Malaysia, Philippines, Thailand, and more, reinforcing Hong Kong’s position as a major food and beverage trading hub in the region. The ICMCM, organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also successfully concluded on 16 August.Sophia Chong, HKTDC Deputy Executive Director, said: “This year, for the first time, four theme days featured across all fairs contributing to their resounding success. Well-designed, exciting and innovative activities drew large crowds, fuelling visitor spending. This year, the introduction of a dedicated Halal food and beverage label, on products from more than 100 exhibitors at the Food Expo PRO and Food Expo was welcomed by buyers and the public visitors. We were pleased to see the Hong Kong International Tea Fair continue to gain strong support from regional pavilions and exhibitors. The five fairs successfully created significant business opportunities for exhibitors, and a vibrant shopping destination for the public.”Over 90% of local exhibitor accepted electronic payment methods with per capita spending reached HK$1,615Over 90% of local exhibitors at the Food Expo, Beauty & Wellness Expo, and Home Delights Expo accepted electronic payment. In a survey conducted on-site by the HKTDC. More than 50% of about 1,500 respondents said they had spent HK$1,000 or more at the exhibition. Nearly 85% of respondents said they paid electronically, emphasising how e-payment boosts spending by offering visitors ease and convenience. The overall per capita spending was estimated at HK$1,615; a year-on-year rise of more than 6%.Strong consumption fuelled by encouraging sales resultsThe city’s premier annual Food Expo is dedicated to showing the world’s finest cuisine and wines.Taiwan exhibitor Grass Lands Food Co., Ltd. exhibited at the fair for the first time and achieved great results with a whole container crispy jerky and chewy jerky sold out by the fourth day of fair. According to Yu-Hung Wang, manager of Grass Lands Food Co. Ltd, said, “Many consumers from Mainland China and Hong Kong showed great interest in our jerky products and the sales were exceptional and far exceeded our expectation. We successfully promoted our brand and products at the fair."The Beauty & Wellness Expo showcased quality products, including popular home-use beauty devices, skincare brands, hair care products, and more. The Korean beauty brand, medicube, returned to the fair with an enlarged booth of 96 square metres. The brand’s senior associate of beauty marketing team, Julie An, saw a lot of potential in Hong Kong for Korean beauty brands and brought two more brands to this year’s fair. Their best seller was the medicube’s AGE-R Booster Pro beauty device with an average daily sales volume of more than 1,000 sets at the special Expo price of HK$1,700 each. Other medicube beauty products were also well-received by Hong Kong consumers with new customers responsible for more than 75% of sales.The Home Delights Expo featured massage chairs, smart home technology, stylish homeware, bedding and furniture. Giormani, a custom-made sofa specialist renowned for its quality and design, made its first appearance at the Home Delights Expo this year. Shop Manager, Kenji Wan, said the booth attracted a lot of attention from new customers. With the special discounts of up to 59% off to stimulate onsite sales, they expected a sales turnover of approximately HK$2 million.Trade fairs opened doors to new business opportunities for Halal productsThe Food Expo PRO brought together leading food and beverage companies, technology enterprises and representative organisations from countries and regions around the world.In line with the growing interest in Halal food, a new label was introduced to help buyers easily identify and source Halal food and beverages. Joseph Leung, senior adviser of business development at Haichang Ocean Park Holdings Ltd, a developer of a marine theme park resort in Saudi Arabia, placed substantial orders with exhibitors from Thailand and Mainland China, securing annual contracts worth up to US$500,000 of Halal-certified rice and tea.The Food Science and Technology zone showcased the latest food products, services and technology to help the industry explore business opportunities. Elevatefoods Technology showcased their patented smart 3D food printing and multi-level cooking technology. Connie Lee, Co-founder and CEO, said: “Food tech is a fast growing trend in the industry and the Food Expo PRO served as a solid platform to launch our innovation and technology with buyers from Japan, Korea, Singapore, Thailand and Vietnam showing interest in our 3D food tech devices.” Food Expo PRO also welcomed 20 pavilions from different countries and regions. Panita Shinawatra, Acting Director General of Thailand’s Small and Medium Enterprises Promotion, said they have lined up 10 food producers from Thailand to promote Thai-style food and beverage products at Food Expo PRO. They received very strong response in particular from buyers from Mainland China and Hong Kong and orders worth more than US$300,000 were secured for snacks, seasoning and other products.Abdul Rahman, CEO of Trans-Atlantic Trading Company Limited from Kenya, exhibited at the Hong Kong International Tea Fair for the first time and established links with 15 buyers from Mainland China, Hong Kong, Egypt, Malaysia, Singapore and Vietnam. The company expects to receive new orders worth US$2 million directly from the fair.Hybrid mode connects local and international business opportunitiesThe Food Expo PRO and the Hong Kong International Tea Fair operated under the hybrid model EXHIBITION+, allowing global food and tea buyers to connect through physical and online platforms. Click2Match, a smart business matching platform, will continue to facilitate online meetings until 24 August.ICMCM fosters collaboration and advances the industry through dynamic exchangesThe ICMCM, organised by the Modernized Chinese Medicine International Association (MCMIA) in partnership with the HKTDC and ten scientific research institutions, drew to a successful conclusion. The conference fostered insightful discussions on timely industry issues, including opportunities and challenges in Chinese medicine research, and cross-regional exchanges and development of Chinese medicine products in the Greater Bay Area.Held alongside the Food Expo, Beauty & Wellness Expo, Home Delights Expo, the Food Expo PRO and the Hong Kong International Tea Fair, the conference contributed to a dynamic, multi-faceted event encompassing food, beauty, health, household goods, and Chinese medicine. This synergy fostered a vibrant platform for cross-industry exchange and collaboration.Photo download: https://bit.ly/4cMH1S9Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo, Beauty & Wellness Expo, and Home Delights Expo, and the two trade fairs — Food Expo PRO and Hong Kong International Tea Fair drew to a successful close. The five fairs attracted over 500,000 visitsThe Food Expo PRO welcomed 20 pavilions from different countries and regions, including multiple provinces in Mainland China, the neighbouring Japan and Korea, Thailand, Indonesia, Malaysia and Philippines from the ASEAN region, Poland and Mexico from outside Asia, and moreThe Hong Kong International Tea Fair featured four pavilions: Sri Lanka, Fujian, Hunan, and the first-ever pavilion by the Hong Kong and Kowloon Tea Trade Merchants AssociationOn the fair opening day (15 August), the theme “Delights Across Mainland China” introduced visitors to famous dishes from various regions of Mainland China. The China National Agricultural Pavilion, organised by the Agricultural Trade Promotion Centre, the Ministry of Agriculture and Rural Affairs of Mainland China, showcased over a thousand agricultural and food products from 12 provinces in Mainland China“Happy Friday” on 16 August featured mixology shows by star mixologists and food crafting demonstrations showcasing culinary aesthetics. A wide selection of fine wines was available at promotional prices at the Food Expo's Gourmet ZoneOn 17 August, “Japan & Korea Express” Day immersed visitors in the vibrant culinary and lifestyle trends of both countries, including experiencing the grace of traditional Japanese dance and the skill of judo demonstrations, kimchi-making demonstrations by a Korean chef, seminars on Korean health foods, and taekwondo and dance performancesSpanning over the weekend from 17-18 August, the "Wellness Weekend" offered seminars and workshops, including sessions on healthy tea brewing. The “Youth Hair Salon” organised by the Hong Kong Hair & Beauty Merchants Association, offered on-site haircuts daily during the ExpoThe fairs came alive with popular and engaging events, such as the Star Chef cooking demonstrations, Smart Bidding sessions and lucky drawsThe hybrid International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM) was themed "The Industry-University-Research Collaboration and Clinical Research on Traditional Medicine", and featured 18 keynote speakers from Hong Kong, Mainland China and overseas who discussed development trends, scientific research achievements, successful experiences, regulations, and the outlook of Chinese medicine and health products in connection to the “Belt and Road” initiativeFor more information, please visit:HKTDC Food Expo PROfoodexpopro.hktdc.com/HKTDC Hong Kong International Tea Fairhkteafair.hktdc.com/HKTDC Food Expohkfoodexpo.hktdc.com/HKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.com/HKTDC Home Delights Expohomedelights.hktdc.com/Media EnquiriesOgilvy Public Relations:HKTDC’s Communications and Public Affairs Department:Cynthia Sit (852) 9425 4547 cynthia.sit@ogilvy.comFrankie Leung (852) 2584 4298frankie.cy.leung@hktdc.orgLeanne Pok (852) 9379 9694leanne.pok@ogilvy.comClayton Lauw (852) 2584 4472clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月19日 - (亚太商讯 via SeaPRwire.com) – 持有花园道三号及朗豪坊物业的冠君产业信托（股份代号：2778）公布截至 2024 年 6 月 30 日止的中期业绩。业绩摘要 2024上半年2023上半年变动租金收益总额 （百万港元）1,1151,168- 4.5%物业收益净额（百万港元）954995- 4.1%可分派收入（百万港元）544617- 11.9%每基金单位分派（港元）0.08090.0927- 12.7% 于2024年6月30日于2023年12月31日变动物业组合总值（百万港元）61,40662,950- 2.5%每基金单位资产净值（港元）7.427.72 - 3.9%资产负债比率23.1%22.8%+ 0.3 pp概览本信托2024年上半年业绩继续受到高息环境所影响。虽然整体旅客人数稳健增长，但港元偏强遏抑消费，促使本地人外游。朗豪坊商场的零售销售继续优于市场表现，而香港写字楼租赁市道因供应情况而受压。随着成功完成再融资，本信托共有40亿港元的已承诺备用信贷额度，足以应付2024和2025年所有再融资需求。面对充满挑战的宏观经济环境，本信托的可分派收入下跌11.9%至5.44亿港元，而每基金单位分派（「每基金单位分派」）则减少12.7%至0.0809港元。花园道三号尽管市场供应充裕，花园道三号的出租率仍然展现韧性。我们留意到有更多来自资产管理公司和家族办公室的租赁查询，并于报告期内引入一批新的小型租户。于2024年6月30日，写字楼出租率为82.3%。由于续租租金于上半年持续下跌，该物业的租金收益减少9.0%至5.71亿港元（2023年：6.27亿港元）。朗豪坊办公楼朗豪坊办公楼仍然是生活时尚及大健康总汇，于2024年6月30日，生活时尚行业租户所占面积达69%。由于疫后内地医疗美容旅游的复苏速度比预期慢，一些美容和医疗租户缩减了他们的业务规模。朗豪坊办公楼的出租率于2024年6月30日为87.1%。租金收益则下跌4.5%至1.66亿港元（2023年：1.74亿港元）。朗豪坊商场朗豪坊商场于报告期内的表现继续优于香港整体零售市道。尽管上半年香港零售销售下跌6.6%，商场租户的销售额却录得2.3%的升幅，而美妆美容类别继续成为增长动力。于2024年6月30日，商场再度回复悉数租出的状态，租金收益亦升至3.78亿港元（2023年：3.66亿港元）。分派本信托期内可分派收入下跌11.9% 至5.44亿港元（2023年：6.17亿港元），而每基金单位分派则减少12.7%至0.0809港元（2023年：0.0927港元）。按2024年6月28日的基金单位收市价1.57港元计算，相当于年度分派率10.3%。资产值于2024年6月30 日，本信托旗下物业组合的估值为614亿港元，较2023年12月31日的629亿港元减少2.5%。可持续发展我们继续在旗下物业及整个价值链中推动可持续发展。花园道三号在取得能源与环境设计先锋（LEED） v4.1铂金评级认证，以及WiredScore楼宇通讯v3.1的铂金级认证后，成为香港首个荣获「四铂金」认证的既有建筑。我们持续加强与租户和持份者的策略伙伴关系，其中一个重要举措是今年七月举办的「ESG周」，汇聚逾20家合作伙伴及参与机构，举办了一系列具影响力的多元化活动。展望虽然市场普遍预期利率将于2024年下半年开始下跌，但减息幅度仍存在不确定性。全球经济前景亦因地缘政治紧张和政策风险而蒙上阴影。写字楼组合方面，我们会在租赁策略上保持灵活，以满足租户的要求。我们亦会持续优化朗豪坊商场的租户组合，积极引进首次进驻香港的品牌，以增加商场对本地消费者和游客的吸引力。我们将因时制宜，灵活变通，以适时应对各种市场变化。图一、行政总裁侯迅女士 (左) 及投资及投资者关系总监陆嘉萍女士 (右)图二、行政总裁侯迅女士有关冠君产业信托(股份代号：2778)冠君产业信托拥有及投资提供租金收入的写字楼及零售物业。信托主要投资位于优越地点的甲级商用物业。现时拥有花园道三号及朗豪坊两幢位于香港的地标性物业，并以合资股权形式拥有位于伦敦市中心的 66 Shoe Lane，总楼面面积约300万平方呎，让投资者可直接投资于优质甲级写字楼及零售物业。信托于 2023 年荣获全球房地产可持续性标准（GRESB）的最高五星级别。网站: www.championreit.com传媒联络方法：纵横财经公关顾问有限公司李惠儿电话：2864 4834电邮：vicky.lee@sprg.com.hk吴宛蓉 电话：2114 4952电邮：cynthia.ng@sprg.com.hk欧阳田宇电话：2864 4848电邮：theresa.ouyang@sprg.com.hk网站: www.sprg.com.hk Copyright 2024 亚太商讯 via SeaPRwire.com.

RIYADH, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - Saudi Arabia has navigated significant challenges in developing its data center infrastructure and 5G networks. Initially, the country faced hurdles such as high costs, regulatory barriers, and the need for substantial technological upgrades. However, through strategic investments and partnerships with global technology leaders, Saudi Arabia has steadily advanced its digital landscape.Initiatives like Vision 2030 have been pivotal, promoting digital transformation as a national priority. The government has implemented policies to foster innovation, streamline regulations, and attract foreign investments. Moreover, substantial funding in research and development, alongside the establishment of tech hubs and smart cities has accelerated progress. This resilience and forward-thinking approach have enabled Saudi Arabia to overcome early obstacles, positioning it as a burgeoning digital hub with a robust 5G and data center ecosystem, ready to support the nation's ambitious economic and technological goals.5G can transform Saudi Arabia into a Gigabit society, offering speeds up to 100 times faster than 4G and latency as low as 1ms. This technology enables telecom operators to ease network congestion in high-density areas, significantly enhancing the consumer experience while reducing the cost per bit. The result is a more efficient, reliable, and high-speed connectivity that supports the country's digital transformation and technological advancements.Overview of the event: The Data Center Xpo: where innovation meets strategy in the digital era. As data grows in importance, this summit is a beacon for professionals. Join visionaries and experts to explore trends, exchange viewpoints, and unveil transformative solutions. Beyond limits, it's a hub for networking, learning, and collaboration with insightful sessions, workshops, and discussions on data analytics, AI, and emerging tech.From demystifying the intricacies of data to deciphering the forthcoming wave of technological progress, the Data Centre Xpo seamlessly transforms knowledge into actionable insights. This conference is positioned to foster connections, forge partnerships, and unleash the limitless potential of excellence driven by the strategic application of data-driven solutions.Who will attend?Sultan Moraishedi, Group Chief Cybersecurity, Data And Business Excellence Officer,Red Sea Global.Abdullatif AlBlowi, Director Of Innovation And Technology Communications, Space & Technology Commission - CST.Anas Mosa,IT Director ,PIF Projects.Fahad Mahmoud Bedaiwi, Executive Vice President,Head Of Facilities, Management And Engineering,The Saudi National Bank.Mohammed Shah,IT & Smart City, Director Knowledge Economic City.Ahmed AlThuhaibi, Chief Of IT, Saudi Pro League.Kamal Farag, Digital Services Director,Human Resources Development Fund - HRDF - KSA.Mushtaq Ahmed, Enterprise Architecture And Digital Strategy Director, Saudi Post-SPL.Abdullah Abdulwasa, Chief Digital Officer, Al- Faisaliah Group.Sulafah Jabarti, Chair of the Digital Economy Committee, International Chamber of Commerce - Saudi Arabia.The event will cover topics like:Synergy Unveiled 5G Networks and Data centres Shaping Tomorrow's Digital Eco System.Unleashing the Potential of Al in Data Center Management.Efficient Remote Management Strategies for Modern Data Center.Unleashing the Power of Hyper Scalability Transforming the Data Center for Ultra Responsive Performance.Navigating the Hybrid Cloud Landscape.Towards Sustainable Computing Implementing Green Data Center Strategies.For more information and to register for Data Center Xpo click the link: https://exito-e.com/datacenterxpo/saudi/About ExitoExito, which means success in Spanish, embodies our commitment to the success of our customers. Each year, we host over 240 virtual and in-person conferences globally, bringing together audiences with world-class thought leaders and C-level executives across industries. Our meticulously crafted agendas, based on extensive research and valuable industry insights, facilitate business, knowledge transfer, deal flow, and impactful messaging for brands.For Media Enquiries, contact:Kasturi Nayak (Sr. Marketing Executive)Kasturi.nayak@exito-e.comEnquiry@exito-e.comExito Media Concepts Copyright 2024 ACN Newswire via SeaPRwire.com.

ISTANBUL, August 19, 2024 (ACN Newswire via SeaPRwire.com) - Türkiye received $4.7 billion in international direct investment in the first six months of this year. The Netherlands, the USA, Germany, Ireland, Norway, and the United Kingdom were the countries from which Türkiye received the most investment capital.BankPozitif's Chairman, Dr. Erkan KorkCommenting on the issue, BankPozitif Chairman Dr. Erkan Kork stated that despite the global decline in international direct investments, Türkiye has performed better, saying, "Our country is attracting significant investments from global actors with its entrepreneurial business culture, young population, and competitive products and services. Over the last 20 years, Türkiye has become a country that attracts 1% of the world's investments annually. The goal is to increase this rate to 1.5% by working even harder. Türkiye is not far from this target with the political stability provided by our President Recep Tayyip Erdogan, the reforms implemented, infrastructure investments, and investor-friendly policies. Under the vision and determined stance of our Minister of Treasury and Finance, Mr. Mehmet Simsek, our country is on the path to becoming a center for international investments.""It would be no surprise to hear news of new investments"Noting that Türkiye would achieve a much different picture with price stability, Kork said, "Türkiye Cumhuriyet Merkez Bankası Governor Fatih Karahan and his team are, so to speak, working tirelessly day and night. The improvement in the current account balance is evident. Recently, with the increase in our reserves and the correct steps taken, the Turkish Lira has reached an attractive position. Achieving price stability opens the door to the process leading to financial stability. In a country where there is financial stability, the appetite for investment is high," he said."Large-scale investments will come in the fintech sector"Dr. Erkan Kork stated that Türkiye would continue to attract qualified investments, especially those focused on the export of goods and services, saying, "The total value of international direct investment inflows to our country since 2002 has exceeded $268 billion. The investments received in the first six months of 2024 accounted for 28% of the current account deficit. This rate will increase further. Türkiye, which is a production, logistics, and management center for international investors, will continue to attract technology investments, particularly in fintech and e-commerce. I believe that capital inflows will continue not only from Europe and the USA but also from the Gulf countries," Dr. Kork said.About BankPozitifOperating in the field of digital banking, BankPozitif is a Turkey-based financial institution that enables individuals and businesses to carry out their financial transactions quickly and efficiently through a single digital platform. The bank offers digital investment banking with personalized financial solutions and innovative technologies for its customers. Source: BankPozitif [https://www.bankpozitif.com.tr]This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire (www.emailwire.com) – the gloabal newswire that provides Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.

Highlights:Strong analytical results from the inaugural drilling campaign for Q2 Metals including:CS-24-010: Cumulatively 181.1 metres ("m") at 1.67% Li2OWidest interval of 120.3 m at 1.72% Li2O including 19.0 m at 2.06% Li2OCS-24-007: Cumulatively 94.6 m at 1.52% Li2OWidest interval of 27.1 m at 1.96% Li2O including 11.1 m at 2.49% Li2OCS-24-008: Cumulatively 27.0 m at 1.63% Li2OWidest interval of 19.3m at 1.75% Li2O including 6.2 m at 2.23% Li2OCS-24-009: Cumulatively 115.9 m at 1.48% Li2OWidest interval of 82.1m at 1.43% Li2O including 15.7 ma t 1.88% Li2OVancouver, BC, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - Q2 Metals Corp. (TSX.V:QTWO)(OTCQB:QUEXF)(FSE:458) ("Q2" or the "Company") is pleased to report on the first core assay results from drill holes CS-24-007 to CS-24-010 from the Spring 2024 Drill Campaign at the Cisco Lithium Property (the "Property" or the "Cisco Property") located within the greater Nemaska traditional territory of the Eeyou Istchee James Bay region of Quebec, Canada."These first four holes of our inaugural drill program at Cisco have exceeded our expectations with higher grades within some of the wider intervals such as Hole 10," said Q2 Metals VP of Exploration, Neil McCallum. "We look forward to releasing more analytical results in the coming weeks as they become available.""Between closing our financing earlier this month and the work we've done in the field, 2024 has been an exceptional year for Q2 Metals so far," said Q2 Metals President and CEO, Alicia Milne. "We have just begun our work at the Cisco Property, and having only completed 12 drill holes, these initial results are exceptionally promising."The analytical results reported herein represent the first 1,017 m of drilling over four (4) holes of the 3,753 m that were drilled over 12 holes at the Cisco Property. Initial visual results of those four holes were reported by the Company on June 17, 2024.The Spring 2024 Drill Campaign was designed to expand upon the 2023 drilling by the Property vendors. Hole CS-23-05 ("Hole 5") drilled by the Property vendor ended in pegmatite and assays results confirmed a total of 115.4 m at 1.40% Li2O, cumulatively within five (5) separate pegmatite intervals. Holes CS-24-009 and 010 ("Hole 10") were designed as 50 m westward step-outs from Hole 5. Assay results from these two holes confirmed wide intervals of spodumene pegmatite, with the widest interval reaching 120.3 m at 1.72% Li2O, including 19.0 m at 2.06% Li2O in Hole 10.Complete highlighted intervals from holes CS-24-007 to 010 are summarized in Table 1 and represented in Figure 1. All intervals of greater than two (2) metres of core-length are included in the table. Internal dilution of non-pegmatite material was limited to intervals of less than five (5) metres. No specific grade cap or lower cut-offs were used during grade and width calculations. All intervals are reported as core widths and mineralized intervals in all the holes drilled thus far are not representative of the true width as the modelled pegmatite zones are being refined with every additional hole.Figure 1. Map of Inaugural Drill Hole Analytical Results at Cisco PropertyTable 1. Summary of Analytical Results of Spring Drill Holes at Cisco PropertyResults from approximately 2,700 m of drilling eight (8) holes (CS-24-011 to CS-24-018) remain to be reported from the Spring 2024 Drill Campaign and will be released as soon as results are available. Drilling at the Cisco Property is ongoing and will continue into the fall of 2024.About the Cisco PropertyThe Cisco Property is comprised of 222 mineral claims and is 11,374 hectares in size. It is located less than 10 kilometres ("km") east of the Billy Diamond Highway, and is approximately 150 km north of Matagami, a small town that contains the closest rail link to much of James Bay. The Property lies within the greater Nemaska Community lands of the Eeyou Istchee Territory, James Bay, Quebec.The Property is situated along the Frotet Evans Greenstone Belt, comprised of a volcanic package dominated by mafic to felsic metavolcanic rocks, of the southern James Bay Lithium District, the same belt that hosts the Sirmac and Moblan lithium deposits, located 130 km and 180 km away, respectively.Sampling, Analytical Methods and QA/QC ProtocolsAll drill core samples were shipped to SGS Canada's preparation facility in Val D'Or, Quebec, for standard sample preparation (code PRP92) which includes drying at 105°C, crushing to 90% passing 2 mm, riffle split 500 g, and pulverize 85% passing 75 microns. The pulps are then shipped by air to SGS Canada's laboratory in Burnaby, BC, where the samples are homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (code GE_ICM91A50).A Quality Assurance / Quality Control protocol following industry best practices was incorporated into the sampling program.Qualified PersonNeil McCallum, B.Sc., P.Geol, is a registered permit holder with the Ordre des Géologues du Québec and Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, and has reviewed and approved the technical information in this news release. Mr. McCallum is a director and VP Exploration for Q2.About Q2 Metals CorpQ2 Metals is a Canadian mineral exploration company focused on unlocking its portfolio of lithium projects in the Eeyou Istchee James Bay region of Quebec, Canada, that includes both its 100-per-cent-owned Mia Lithium Property and the Cisco Lithium Property.The Cisco lithium property is located approximately 150 km north of Matagami, Que., and comprises 222 mineral claims and is 11,374 ha in size. The property has district-scale potential with an already identified mineralized zone and a discovery drill result of 115.4 metres at 1.40 percent lithium oxide (hole CS-23-05), cumulatively in five separate pegmatites.FOR FURTHER INFORMATION, PLEASE CONTACT:Alicia MilnePresident & CEOAlicia@Q2metals.comJason McBrideCorporate CommunicationsJason@Q2metals.comTelephone: 1 (800) 482-7560E-mail: info@Q2metals.comWWW.Q2Metals.comFollow the Company: Twitter, LinkedIn, Facebook, and InstagramForward-Looking StatementsThis news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company's properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions.Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date specified in such statement. Forward looking statements in this news release include, but are not limited to, drilling results on the Cisco Property and inferences made therefrom, the potential scale of the Cisco Property, the focus of the Company's current and future exploration and drill programs, the scale, scope and location of future exploration and drilling activities, the Company's expectations in connection with the projects and exploration programs being met, the Company's objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, variations in ore grade or recovery rates, changes in project parameters as plans continue to be refined, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedarplus.ca.Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.SOURCE: Q2 Metals Corp. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) - 百利达集团控股有限公司（「百利达集团」或「集团」，股票编号：8179.HK）欣然公布，截至二零二四年六月三十日止未经审核中期业绩，业绩表现良好，期内降本增益成果显著，业务规模及盈利能力持续上升，中期纯利升5.05%，毛利率升至约22.1%。业绩亮点：葡萄酒贸易续为主营业务 推动集团毛利率上升集团的葡萄酒主要来自多个著名澳洲葡萄园及酿酒厂，着重以优质葡萄酒为主要产品。 2024年中期，葡萄酒贸易继续为集团最大收益分部，期内收益约218.8百万港元，同比略微减少30.3百万港元;分部溢利45.2百万港元，同比微降0.4%。 主要受国内前景不明朗及消费者购买力下降所影响，然而得益于供应商提供更多折扣及产品销售套餐，使得销售成本减少15.81%，从而带动集团毛利率提升3.4个百分点至22.1%。 集团日前正积极拓展本地市场，包括参加各类展览会、在不同地区发展销售网络及代理，并透过新零售模式建立多种销售渠道。展望未来，集团葡萄酒产能稳步提升。 2024年在收获葡萄的同时，集团正在生产约55,000升葡萄酒。 产能的增加将使集团能够推出新品牌、开发罐装红葡萄酒以及进行产品升级。 相信该等措施将更能满足不同消费者群体不断变化的需求及偏好。 未来集团亦不排除将与有影响力的合作伙伴合作，从而持续建立品牌认知度，提升品牌价值。 相信随着「百利达」品牌价值的不断提升，能对集团销售额及市场份额带来正面拉动，从而增加收入和利润，进而带来更大的股东价值。食品业务审慎经营 新产品饮用水拓无限商机集团食品业务主要包括澳洲百鹤年橄榄油等，于2024年中期，食品业务收益约为43,000港元。 集团计划于今年下半年开始推出源自慕士塔格峰的优质饮用水产品。饮用水产品较其他软性饮料需求更为刚性，是外出场景解渴、室内场景饮水的首选。 且随着居民健康意识提升，瓶装水对其他含糖饮料的替代也有望为产业发展贡献增加。 瓶装水为中国软饮行业界第一大赛道，数据显示，2023年，中国瓶装水产业市场规模达2,266亿元人民币，同比增长2.8%，销售量则为528.8亿公升，同比增长1.1%; 预计2026年中国瓶装水市场规模将成长至2,485.9亿元人民币，未来三年CAGR为3.1%，销量将成长至545.2亿升。 相信集团优质饮用水新产品将继续受益于瓶装水好赛道带来的无限商机。 集团亦会持续关注市场情况，积极寻求潜在的增长及扩张机会。百利达集团主席兼执行董事黄巍女士表示：「百利达集团正积拓展市场，不断提升品牌价值，从而吸引更多本地市场及亚太地区的潜在客户。 展望未来，集团将维持审慎的经营策略，集中资源开发最具增长潜力及盈利能力的商机 ，以维持盈利能力及稳定的业务经营，以最大程度提升股东回报。」- 完 -关于百利达集团控股有限公司百利达集团控股有限公司于1998在香港成立， 2011年在香港联合交易所有限公司创业板上市。 集团目前的主要业务为葡萄酒贸易业务、及于香港生产及销售食品。百利达集团的葡萄酒贸易业务旨在利用香港葡萄酒业的稳定增长，是发展集团分销和批发渠道的良机，并有助于使集团业务多元化。 集团主要品牌「百利达」的葡萄酒主要来自多个著名澳洲葡萄园，着重以优质红酒为主要产品。 集团的葡萄酒现已销往超过12个国家和中国28个地区，并在韩国新罗免税店及韩国现代百货免税店上架，广受五星级酒店、航空公司以及各类中式、日式、西式餐厅等欢迎。 同时，集团自2006年开始生产、销售及分销食品，食品业务分部透过自营零售店为香港客户生产及供应烧腊及台式卤味等食品，及供应至香港的本地大型连锁超市等。传媒查询：意博資本文化有限公司 电话: 3476 2915 电邮: ir_palinda@vsfg.com Copyright 2024 亚太商讯 via SeaPRwire.com.

SINGAPORE, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - The Perse School (Singapore) (TPSS) has won the tender conducted by the Economic Development Board (EDB) and Singapore Land Authority (SLA) in the first half of 2024 to provide foreign system education on the site at 58 Chestnut Drive.Under new leadership, led by CEO Johan Stromsater and school principal, Daniel Cross, TPSS targets a launch on the new campus in January 2025 with a future-focused Cambridge curriculum to equip students with academic, critical thinking, problem-solving, and leadership skills. TPSS is working towards ERF registration, and subject to regulatory approval, will open to students from 3-11 years of age from January 2025 and extend to include 12-18 years of age from 2026. This development marks the beginning of an exciting phase for TPSS as the new management seeks to offer a blend of British academic excellence, co-curricular opportunities, and pastoral care for students with fees starting at $22,750 per year."We are excited to bring The Perse's long-standing tradition of excellence to the International School sector in Singapore at a fee level that will make a top tier British education attainable," says Johan Stromsater, CEO of TPSS. “Our mission is to nurture happiness and success among our students, and we are committed to developing a diverse student community and an inspiring educational environment where every student can thrive."“Singapore’s diverse and high-quality selection of Foreign System Schools enhances our competitiveness as an attractive location for international companies and global talent. The Perse School (Singapore) will add to the landscape and serve the varied education needs of expatriate families here,” said Ms Ho Weng Si, Senior Vice President, Industry Manpower Development, EDB.The leadership team comprises:Johan Stromsater: CEO of Futuris Education and now CEO of TPSS, previously served as CEO of the Canadian International School in Singapore.Daniel Cross: Founding Principal of TPSS, is relocating to Singapore from Cambridge after 24 years at The Perse School Cambridge, most recently as Senior Deputy Head. "I am thrilled to bring the rich traditions and academic excellence of The Perse School to Singapore. We aim to provide a world-class education that blends academic rigour with a modern, future-focused skills curriculum."Kephren Sherry will be the Head of Pelicans (Early years) and Junior School, with 28 years in education and 12 years in the international school system. "Joining The Perse School Singapore is an incredible opportunity to shape the future of education for thousands of children."Innovative CurriculumTPSS will offer a comprehensive education from early years (3 years) to senior school (18 years). The school's curriculum will prepare students holistically for the challenges and opportunities of the future, equipping students with academic rigour, critical thinking, problem-solving, and leadership skills. The Pelican Junior and Senior programs will follow the International Cambridge curriculum until iGCSE, with Years 12 and 13 adopting the International Baccalaureate (IB). The curriculum will have a strong emphasis on STEM subjects and bilingual programs, and will also integrate skills such as robotics, coding, and entrepreneurship into the core timetable.State-of-the-Art FacilitiesThe new campus will be located at 58 Chestnut Drive, the former site of Chestnut Drive Secondary School. The campus is undergoing significant renovations to create a state-of-the-art learning environment, with facilities that will include modern classrooms, a multi-purpose sports field, and specialised arts, music, and drama learning spaces. The first phase of the development is expected to be completed in time for the school opening in January 2025, with further development phases planned outside of school term time throughout 2025.Mission and Values of The Perse School SingaporeTPSS is under licence from The Perse School Cambridge International who will closely support the schools design and setup. With over 400 years of British academic excellence and heritage, the setup will be guided by a commitment towards academic excellence, extracurricular activity, and pastoral care to nurture well-rounded students. This is underpinned by The Perse core values of Endeavour, Intellectual Curiosity, Breadth and Balance, and Care for One Another and the Environment.Ed Elliott, Head of The Perse School Cambridge, remarks: "The close collaboration between our campuses will ensure the consistent delivery of The Perse's high standards and values. In a typical year, 40-50 Perse Cambridge pupils will receive offers from Oxford or Cambridge Universities. Perse Cambridge students received a combined 718 university offers this year, including 589 from the UK's prestigious Russell Group universities. Our success in university placements stems from an excellent academic education, complemented by our commitment to individual personal development through extracurricular programs like our Perse Exploration Society. These initiatives prepare students for further education, employment and adult life. Offering pathways to higher education and careers has been a hallmark of The Perse for centuries, and we aspire to extend these opportunities to our students in Singapore."A bank of imagery available for media use, including the leadership team, can be found on this drive link.About The Perse School (Singapore)The Perse School (Singapore), owned and operated by Future Education PTE LTD, offers an outstanding education affiliated with The Perse School Cambridge International. Perse Singapore's focus is on academic excellence, extracurricular activity, and pastoral care to nurture rounded students. Our core values—Endeavour, Intellectual Curiosity, Breadth and Balance, and One Another and the Environment—guide and shape the school's culture.About The Perse School CambridgeThe Perse School offers an excellent academic education complemented by extracurricular programs like the Perse Exploration Society. For more details, visit www.perse.co.uk.Contact: knsawtell@perse.co.uk or sdarmitage@perse.co.ukContact Information:For media enquiries or more information, please email Contact@perse.com.sg. Social Media Links:Facebook Instagram: @Theperseschoolsingapore LinkedIn http://www.Perse.com.sgFor more information, please visit www.perse.com.sg Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - A clear testament to the success of its past editions, Rockbird Media is thrilled to announce the 12th Retail & E-Commerce Summit Asia, set to unfold on September 26, 2024, at the One Farrer Hotel in Singapore. Themed “Retail Revolution: The Limitless Growth in the Age of AI,” this premier event is poised to dive deep into the seismic shifts reshaping the retail and e-commerce landscape.Despite its smaller population compared to regional neighbors, Singapore is on track to achieve a remarkable US$5,901 million in retail and e-commerce revenue by 2024. This impressive growth highlights the city-state's burgeoning role in the global digital economy and underscores the urgent need for businesses to adapt and thrive in this dynamic environment.The summit will offer an unparalleled opportunity for industry professionals to explore the latest trends and technologies driving the retail revolution. Attendees will benefit from keynote presentations, interactive breakout sessions, and panel discussions featuring leading experts. Personalized agendas, 1-on-1 meetings, and vibrant networking sessions will also be integral to the event, ensuring that each participant gains actionable insights and valuable connections.Singapore stands at the forefront of e-commerce innovation, and this summit will provide crucial insights into harnessing AI and technology for limitless growth, bringing together 100+ industry leaders and experts to shape the future of retail.For more information, including registration details, the in-depth agenda, speaker updates, pricing, and more, please visit https://rockbirdmedia.com/all_b2b/resa-singapore-2024/.About rockbird mediaRockbird media is an international business media company that produces B2B events and offers business solutions.Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow.Media contact:annjubelle@rockbirdmedia.com Copyright 2024 ACN Newswire via SeaPRwire.com.

KUALA LUMPUR, Aug 19, 2024 - (ACN Newswire via SeaPRwire.com) - With rapid HR advancements on the horizon, Rockbird Media is just in time to announce the 16th edition of the HR Leaders & HR Tech Strategy Meeting, taking place on September 24, 2024, at Berjaya Times Square, Kuala Lumpur, Malaysia. The event, themed “Advancing into the Nexus of Human and Technology,” will be a crucial platform for addressing the evolving role of technology in HR.As Malaysia’s HR Technology market is poised for a significant 12% compound annual growth rate (CAGR) over the next five years, this year’s gathering will focus on equipping HR professionals with strategies to integrate cutting-edge tools and bridge the technological skill gap. Attendees will explore methods to enhance operational efficiency, boost employee engagement, and optimize legacy systems with modern technology.One in a series of successful HR Strategy Meetings across Southeast Asia, its 16th edition will emphasize the urgent need for HR leaders to strategically adapt to technological advancements, providing a unique opportunity to engage with industry experts, share best practices, and prepare for the future.The event will feature keynote addresses, interactive breakout sessions, panel discussions, and one-on-one meetings, designed to offer actionable insights and foster networking among over 100+ CHROs and HR leaders from various industries.For more information, including registration details, the in-depth agenda, speaker updates, pricing, and more, please visit: https://rockbirdmedia.com/all_b2b/hrmy2024/About rockbird mediaRockbird media is an international business media company that produces B2B events and offers business solutions.Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow.Media contact:annjubelle@rockbirdmedia.com Copyright 2024 ACN Newswire via SeaPRwire.com.

Results Highlights:- Revenue and net profit reached US$78.9 million and US$18.8 million, respectively.- APAC market revenue grew significantly by 31.0%, driven by both organic growth and contributions from SJ Medicare and PT Revass, the South Korean and Indonesian distributors acquired in Q4 2023.- Total sales volume of proprietary products remained at 717,000 units.- In 1H2024, the Group made extensive efforts to integrate eucatech AG, a German company acquired last year, into its operations and reorganize its production lines, and expects eucatech AG to resume production and shipment in Q3.- The Group has been actively registering products of eucatech AG in various countries and regions, and eucaLimus, a coronary drug eluting stent, has already received registration approval in Malaysia.- For the clinical studies of TricValve, patient enrollment has commenced in 13 hospitals in the PRC. In Japan, the Group is working closely with the Pharmaceuticals and Medical Devices Agency (“PMDA”) and the US Food and Drug Administration (“FDA”) to prepare for the clinical trial and registration process.- In May 2024, the Group engaged the main contractor for its largest R&D and manufacturing facility in Hangzhou, which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million product units upon commencement of production.- The Group’s financial position remained strong, as evidenced by the cash and bank balances of US$246.7 million as of June 30, 2024.- The Group expects to maintain a stable dividend policy, demonstrating its confidence in future prospects.HONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its interim results for the six months ended June 30, 2024 (the “Reporting Period”), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “The global economy has been highly volatile in recent years, as a result of factors such as geopolitical tensions and major central banks shifting their monetary policies. Albeit the challenging external environment, we were able to seize the opportunity to implement a series of measures to enhance operational efficiency and integrate the businesses of SJ Medicare, PT Revass and eucatech AG acquired last year into our Group. We believe the investments made in the first half year are crucial to supporting our future sustainable growth.”For the Reporting Period, the Group’s revenue decreased slightly by 3.1% to US$78.9 million, mainly attributable to decline in sales volume in the US due to integration of Cardiovascular Systems, Inc. (“CSI”) into Abbott Laboratories (“Abbott”), and in the PRC market due to on-going impact of anti-corruption campaign, as well as the Group’s termination of distribution of certain third-party products, despite the significant sales growth recorded in APAC, as well as the modest revenue growth in Japan in terms of Japanese Yen. Excluding the impact of the foreign exchange fluctuations, total revenue would have recorded a slight year-on-year increase of 0.6%. Gross profit amounted to US$55.8 million while gross profit margin stood at 70.7%.Despite the decline in revenue and the short-term increase in expenses incurred by the Group’s series of measures to enhance operational efficiency and integrate the businesses acquired in the previous year, the Group maintained a healthy level of net profit for the first half of 2024. It is worth noting that, excluding the operating expenses of the newly acquired businesses, the three core operating expenses, namely selling and distribution expenses, general and administrative expenses and research and development expenses, for the first half of 2024, remained flat against the same period last year. As of June 30, 2024, the Group maintained a strong financial position with cash and bank balances of approximately US$246.7 million, laying a solid foundation to support its growth objective.Robust Balloon Sales in APAC and EMEAThe Group’s proprietary balloon products continued to gain traction worldwide. In the first half of 2024, revenue from the APAC market saw organic growth of a marked 8.6% year-on-year, thanks to strong balloon sales growth in markets such as Malaysia, Hong Kong, India, Vietnam and Singapore. Particularly, the latest generation of scoring balloon, Scoreflex TRIO, recorded a rapid rise in sales since it was launched in Malaysia in early 2024. Together with the additional contribution of US$4.3 million from the SJ Medicare and PT Revass, distributors acquired in South Korea and Indonesia respectively in Q4 2023, the revenue generated from APAC amounted to a total of US$24.0 million, representing a significant increase of 31.0% year-on-year.In addition, mainly attributable to the increase in sales of the Group’s proprietary balloon products in direct sales markets such as Germany, France and Spain, as well as distributor sales markets including Czech Republic and Slovakia, revenue generated from EMEA slightly increased by 1.3% to US$19.2 million, even being partly offset by the termination of distribution agreement with CSI for atherectomy products.During the first half of 2024, Scoreflex TRIO continued to drive revenue generated from Japan, the Group’s largest single-country market, in terms of Japanese Yen, achieving an 8.1% increase year-on-year.Integrating Newly Acquired Business to Drive Future GrowthFollowing the acquisition of eucatech AG in November 2023, extensive efforts were made to integrate eucatech AG into the Group’s operation and reorganize production lines. The Group has been actively registering eucatech AG’s four products, namely eucaLimus, Support C, Resistant, and VITUS, in various countries and regions to avail those products via the Group’s own sales network to physicians and patients in different markets. In the first half of 2024, eucaLimus was granted registration approval in Malaysia, one of the Group’s direct sales markets. Registration applications for eucatech AG’s products have also been submitted to relevant regulatory bodies in Hong Kong, Malaysia, Switzerland, Italy and Saudi Arabia and are pending approval. The Group also promoted eucatech AG’s products at major conferences including EuroPCR, as well as educated distributors about these offerings so that sales could be ramped up smoothly once the products become available.In April 2024, the Group supported eucatech AG’s on-site Medical Device Directive (“MDD”) and Medical Device Regulation (“MDR”) surveillance audit, as such, was able to extend the CE Mark expiration dates for their 4 products under the MDD framework. All these efforts are expected to see eucatech AG resume production and shipment in the third quarter of the year.Relentless Drive to Translate Innovations into Thriving Product LinesAs of June 30, 2024, OrbusNeich had an aggregate of over 50 approved products. The Group has maintained a steadfast commitment to translating its R&D efforts into commercially successful products. To date, the Group achieved major milestones, including:- Obtaining NMPA approval for Teleport Neuro, FDA approval for Teleport XT and JADE PLUS 14/18/35 OTW, CE Mark for Sapphire ULTRA and Sapphire NC ULTRA;- Submission of registration applications to the NMPA for its Guiding Catheter;- Completion of the clinical trial patient enrollment for Scoreflex TRIO in the PRC, with the NMPA application expected to be submitted in Q3 2024;- Preparation for the Sapphire 3 clinical trial in the US, with enrollment scheduled to begin in Q3 2024.Alongside these regulatory and commercialization efforts, the Group continued to invest in new pipeline products, such as the Corepass modular microcatheter, support catheter and the JADE Plus. Registration applications for these innovative offerings are planned for submission to various authorities in 2024.Meanwhile, the joint venture OrbusNeich P&F made significant efforts to advance the clinical studies of TricValve in two major Asia Pacific markets. Patient enrollment has commenced in the PRC for its clinical trial, and the clinical trial and registration process in Japan is being prepared in close collaboration with the PMDA and the FDA.Boosting Production Capacity through Rigorous Quality Processes and Operational ExcellenceThe Group has always prioritized product quality, which is ensured by a robust quality management system. During the Reporting Period, various sites successfully passed audits conducted by various regulatory and notifying bodies. Furthermore, the Group remains committed to enhancing operational efficiency and reducing production costs by continually optimizing manufacturing processes, work-in-progress inventory levels, and employee productivity. To meet future production needs, the Group will construct its largest R&D and manufacturing facility in Hangzhou, the PRC, for which it engaged the main contractor in May 2024 and which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million units of products upon commencement of production.Mr. Chien concluded: “Looking ahead, as new sales strategies are being executed in the PRC and the US markets, we expect these key geographies will regain growth momentum in second half of the year. Meanwhile, OrbusNeich has maintained active efforts to expand our market presence. On the product front, we are leveraging our comprehensive sales network and brand recognition to market innovative endovascular intervention products to enhance the solutions we provide to the physicians. New products from eucatech AG which is expected to resume production soon will also contribute to improved profitability. We are also actively identifying M&A opportunities that align with our strategic priorities and position us for sustainable growth. Despite the first-half headwinds, we remain optimistic about restoring growth momentum soon and expect to maintain a stable dividend policy for shareholders based on our robust financial position.”- End -About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As of June 30, 2024, OrbusNeich has more than 230 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2024 ACN Newswire via SeaPRwire.com.

业绩亮点：- 收入及纯利分别达78.9百万美元及18.8百万美元。- 亚太地区市场收入显著增长31.0%，主要受惠于内部增长，以及于2023年第四季收购的韩国分销商SJ Medicare及印尼分销商PT Revass所带来的贡献。- 自有产品的总销量维持在717,000件。- 于2024年上半年，集团将去年收购的德国公司eucatech AG与集团的营运整合，并重组其生产线，预期eucatech AG将于第三季度恢复生产及出货。- 集团一直积极在多个国家及地区注册eucatech AG的产品，其中，冠状动脉药物洗脱支架eucaLimus已于马来西亚获批准注册。- TricValve的临床研究方面，OrbusNeich P&F已为该产品于中国13家医院展开病人入组。在日本，集团正与医药品医疗机器综合机构（「PMDA」）及美国食品药品监督管理局（「FDA」）紧密合作，为该产品的临床测试及注册程序作准备。- 于2024年5月，集团已为旗下位于杭州的最大研发及生产设施委聘总承建商，预期于2027年投产，届时将为集团的年产能增加240万件产品。- 于2024年6月30日，集团的财务状况稳健，现金及银行结余达246.7百万美元。- 集团预期维持稳定的股息政策，显示对前景充满信心。香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司（「业聚医疗」或「集团」；股份代号：6929）今天宣布截至2024年6月30日止六个月(「报告期」)的中期业绩。尽管面对不同的市场挑战，集团的收入及本公司拥有人应占期内利润仍分别保持于78.9百万美元及18.8百万美元的水平。业聚医疗董事长、执行董事兼行政总裁钱永勋先生表示：「由于地缘政治局势紧张及主要央行货币政策转变等因素，全球经济近年一直非常动荡。尽管外围环境充满挑战，我们仍能把握契机，采取一系列措施提高营运效率，并将去年收购的SJ Medicare、PT Revass 及eucatech AG与集团的业务整合。我们相信，上半年所作的投资对于支持集团未来可持续增长至关重要。」报告期内，尽管亚太地区的销售录得大幅增长，以及日本市场以日圆计价收入也达到温和增长，然而，由于Abbott Laboratories（「雅培」）对Cardiovascular Systems, Inc. (「CSI」)进行整合令美国销量下跌、中国市场受到反腐运动持续影响，以及集团终止分销若干第三方产品，集团的收入微跌3.1%至78.9百万美元。若撇除外汇波动影响，总收入按年微升0.6%。毛利为55.8百万美元，毛利率达70.7%。尽管收入下降，以及集团为提高营运效率及整合去年收购的业务而采取了一系列措施，导致短期开支增加，但2024年上半年的纯利仍维持稳健。值得一提的是，若撇除新收购业务的营运开支，2024年上半年的销售及分销开支、一般及行政开支及研发开支三项核心营运开支的水平，事实上与去年同期相若。截至2024年6月30日，集团的财务状况稳健，现金及银行结余达约246.7百万美元，为支持集团达致增长目标奠定坚实基础。亚太地区及欧洲、中东及非洲地区球囊销售表现强劲集团的自有球囊产品继续深受全球欢迎。2024年上半年，有赖马来西亚、香港、印度、越南及新加坡等市场的球囊销售额增长强劲，带动亚太地区市场收入取得8.6%的自然增长。特别是最新一代刻痕球囊Scoreflex TRIO，自2024年初在马来西亚推出以来，销量迅速攀升。这加上集团在2023年第四季收购的韩国分销商SJ Medicare及印尼分销商PT Revass在期内带来4.3百万美元的额外收入贡献，推动亚太地区的总收入同比大升31.0%至24.0百万美元。此外，主要受惠于集团的自有球囊产品在直销市场，如德国、法国及西班牙，以及分销市场，如捷克及斯洛伐克的销量有所增加，即使集团与CSI终止有关旋磨产品的分销协议抵销了部分收入升幅，来自欧洲、中东及非洲的收入仍增加1.3%至19.2百万美元。2024年上半年，Scoreflex TRIO继续推动集团最大单一地域市场――日本的收入增长，按日圆计价，较去年同比增长8.1%。整合新收购业务 推动未来增长继2023年11月收购eucatech AG后，集团积极投入各项工作，致力将eucatech AG整合至集团营运，并重组其生产线。集团积极在多个国家及地区注册eucatech AG旗下eucaLimus、Support C、Resistant及VITUS四款产品，以便透过集团自身的销售网络，向不同市场的医生及患者提供这些产品。2024年上半年，eucaLimus于集团的直销市场马来西亚获批准注册，而eucatech AG其他产品的注册申请亦已提交予香港、马来西亚、瑞士、意大利及沙特阿拉伯的相关监管机构，正等待批准。此外，为稳步提升eucatech AG旗下产品上市后的销量，集团于EuroPCR等重要会议上进行推广，并向分销商提供有关产品的资讯。2024年4月，集团为eucatech AG接受关于医疗器械指令（「MDD」）及医疗器械条例（「MDR」）现场监督审核提供支援，从而在MDD框架下延长上述四款产品的CE标志到期日。通过以上举措，eucatech AG有望于今年第三季恢复生产及出货。致力将创新理念转化为丰富的产品线截至2024年6月30日，业聚医疗共有逾50款获批产品。集团一直坚持将研发成果转化为成功商业化的产品，至今已实现多个重大里程碑，包括：- Teleport Neuro获得NMPA批准；Teleport XT、JADE PLUS 14/18/35 OTW获FDA批准；Sapphire ULTRA及Sapphire NC ULTRA取得CE标志；- 向国家药监局提交导引导管注册申请；- Scoreflex TRIO在中国的临床测试病人入组完成，预计将于2024年第三季向国家药监局提交申请；- 现正为Sapphire 3美国临床测试做准备，并计划于2024年第三季在美国开始进行病人入组。除上述监管及商业化工作外，集团亦继续投资于新产品管线，例如Corepass模组化微导管、支撑导管及JADE Plus，并预计于2024年向各监管机构提交该三种创新产品的注册申请。与此同时，合资企业OrbusNeich P&F于两个主要亚太区市场大力推进TricValve临床研究。在中国，临床测试已展开病人入组；而在日本，OrbusNeich P&F与PMDA及FDA紧密合作，准备于日本进行TricValve临床测试及注册。透过严格质量控制及卓越运营流程提升产能集团重视产品质量，并以严格的质量管理系统把关。报告期内，集团多个生产基地顺利通过了不同监管机构及认证机构的审核。此外，集团亦持续优化生产流程、半成品库存及人员的生产力，以提升营运效率及降低生产成本。为满足未来生产所需，集团于中国杭州市兴建旗下最大的研发生产设施，并已于2024年5月委聘总承建商，预期于2027年投产，届时将为集团的年产能增加240万件产品。钱先生总结道：「展望未来，我们预期集团在中国及美国两大主要地域市场实施新销售策略后，此两大巿场将能在今年下半年重拾增长动力。与此同时，我们亦会继续拓展市场据点。产品方面，我们会利用完善的销售网络及品牌知名度，推广创新的血管介入产品， 致力为医生提供更佳的解决方案。而随着eucatech AG即将恢复生产，其新增至集团的产品亦有助加强我们的盈利能力。我们亦正积极物色符合集团策略重点的并购机会，以进一步推动集团可持续增长。尽管上半年面临诸多挑战，我们仍对迅速恢复增长势头保持乐观，并期望在稳健的财务基础上，为股东维持稳定的股息政策。」— 完 —关于业聚医疗集团控股有限公司业聚医疗是一家主要的全球医疗器械制造商，专门生产用于经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）的介入器械。业聚医疗的总部位于中国香港，产品销往全球超过70个国家和地区。集团亦积极将业务扩展至神经血管介入及结构性心脏病领域。截至2024年6月30日，业聚医疗已于全球拥有超过230项授权专利及已公布专利申请，其内部研发团队拥有逾20年的产品开发经验，并已开发出世界领先的专有技术。如需了解更多详情，请访问集团官网：https://orbusneich.com/ Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 2024年8月15日，康哲药业发布2024年中期业绩公告，整体营业额和期间利润环比去年下半年稳步提升。2024年上半年实现营收36.11亿元，同比下降21.7%，环比增长6.1%；若全按药品销售收入计算营收42.88亿元，同比下降22.6%，环比增长8.9%；其中，非国采独家产品及创新产品合计销售收入为人民币24.05亿元，占全按药品销售收入计算营业额的56.1%。实现净利润9.03亿元，同比下降52.8%，环比大幅增长92.8%。2024年，正值康哲药业创新产品商业化的开局之年，也是国家带量采购（国采）对其业绩影响得以释放的关键节点。因黛力新进入第七批国采目录，于2022年11月执行；波依定和优思弗进入第八批国采目录，于2023年7月开始执行；且三款原研药品均未中标，对公司经营业绩带来负面影响。2024年上半年，公司整体业绩环比去年下半年呈现增长态势，标志着康哲药业已基本消化国采影响，成功迈入由非国采独家产品和创新产品驱动业务增长的“新产品时代”。随着莱芙兰（亚甲蓝肠溶缓释片）于今年6月获批上市，美泰彤（甲氨蝶呤注射液）增加成人活动性类风湿关节炎适应症于7月获批上市，康哲药业处于商业化阶段的创新药组合已扩充至5款产品（含6项适应症），并有丰富的差异化创新管线储备。聚创新之能，乘发展之势，康哲药业正以更健康的产品结构全面塑造发展新动能，进一步迎接高质量发展新周期。“合作+自主”双擎研发模式驱动管线量质齐升，加速创新科研成果转化深厚的创新药研发管线是康哲药业长期发展的重要驱动力。公司以坚持满足临床未尽之需，解决患者用药之困为创新目的，以“合作研发+自主研发”双擎驱动，不断布局FIC（全球首创）与BIC（同类最佳）创新产品，并提升研究与临床开发的能力与效率，实现医药科研成果社会和商业价值的快速转化。截至目前，康哲药业中国获批上市的创新产品组合已扩充至5款产品（含6项适应症），其中4款创新药（维图可、益路取、美泰彤-银屑病适应症、维福瑞）已获纳入国家医保目录，并进入规模化临床应用；并新增创新药莱芙兰、美泰彤（类风湿关节炎）在中国获批上市。康哲药业亦稳步推进创新产品临床开发相关工作。目前，德昔度司他片正处于中国NDA审评中；合计约10个项目即将开展/正在推进以注册性随机对照试验（RCT）为主的临床试验。同时，公司不断强化基础研究和自主创新能力，目前已顺利推进10余项自主研究项目，其中三款创新药（VEGFA+ANG2四价双特异性抗体、高选择性TYK2抑制剂CMS-D001片、及GnRH受体拮抗剂CMS-D002胶囊）已进入临床开发阶段。此外，公司创新管线不断扩充。今年3月，康哲药业与Incyte再度达成合作，获得选择性小分子口服JAK1抑制剂povorcitinib在中国大陆、香港、澳门、台湾地区及东南亚11国等国家/地区的研究、开发、注册及商业化产品的独家许可权利，进一步丰富公司在白癜风和其他免疫介导皮肤病治疗领域的产品组合。接下来，康哲药业每年将持续以更高效率、更可控成本源源不断产出创新产品，加速创新价值释放，通过以非国采独家产品和创新产品为主导的健康产品结构，迎接高质量、可持续的业绩增长。成功的商业化体系，高效协同创新产品临床价值释放深耕专科领域32年，成功的商业化能力是康哲药业核心竞争力之一。通过持续强化与整合“开放式商业化平台”，已实现心脑血管/消化、皮肤、眼科三大独立运营业务深入发展，并在关联领域扩张边界；已建立强执行力、高素质的专业推广团队、广泛的渠道与资源覆盖，为公司创新产品实现快速市场准入与品牌塑造奠定了坚实基础。康哲药业四款已进入大规模临床应用的创新药，覆盖中枢神经、皮肤、肾内、消化系统等相关疾病领域，与原有品种在团队和渠道等方面协同增效发展。同时，凭借已获纳入国家医保目录的契机，公司正大力推动医院开发、品牌力建设，真实世界研究，及围绕医学驱动的学术推广工作；并结合患者援助及科普教育项目，提升患者对创新药可及性，推动创新产品临床价值释放。皮肤医美业务“康哲美丽”以皮肤治疗处方产品为核心，轻医美产品和皮肤学级护肤品为延展，不断完善皮肤治疗、皮肤护理和医疗美容全生命周期皮肤健康管理平台。在皮肤处方药临床开发方面，已完成磷酸芦可替尼乳膏白癜风适应症的关键真实世界研究，正在推进中国大陆注册上市申请工作。同时，持续补充再生类轻医美产品矩阵，其中童颜针的中国医疗器械注册申请已于报告期内获受理；并新获三款处于中国注册性临床阶段的再生类轻医美产品，“少女针”、“微晶瓷”、及脱细胞基质植入剂的中国商业化独占许可权利。业绩公告显示，截至6月底，康哲药业推广网络覆盖中国超5.5万家医院及医疗机构，约28万家终端零售药店。通过在心脑血管、消化、中枢神经系统、肾内科、眼科、皮肤科等专科领域优势积累，康哲药业稳步释放专科业务规模效益，高筑业务竞争壁垒，持续构建自身优势专科治疗领域护城河，为多款创新产品和独家品种的商业化带来广阔前景。擘画国际化布局，为增量市场蓄势聚力东南亚业务公司“康联达健康”整合集团化优势资源，将康哲药业在中国市场的成功经验、全球优质产品和创新技术资源外溢共享到东南亚，加速完善东南亚业务“研产销”一体化的开放式平台，为中国和全球药企高质量“出海”战略赋能，也为康哲药业打开更大的增量发展空间。截至6月底，康联达健康已建立有竞争力的产品组合，拥有十余款差异化品种，覆盖肿瘤、中枢神经、自免、皮肤科、眼科等疾病领域。康联达健康正加速推进多款创新储备产品在东南亚各国的上市申请和注册相关工作，如芦可替尼乳膏、亚甲蓝肠溶缓释片、地西泮鼻喷雾剂等；并与君实生物正共同推动特瑞普利单抗（抗PD-1单抗）于东南亚多国的注册进程，以期尽快惠及当地肿瘤患者。去年12月，康哲药业、康联达健康携手康龙化成等共同促成了新加坡生产工厂的收购。今年，各方正持续有序推进该生产工厂的设备检测、质量核查、生产质量体系认证等系列工作，旨在加速CDMO业务进程，并进一步优化集团海外供应链和生产能力。此布局将助力康哲药业未来与全球合作伙伴开展更多产业间合作，共同构建共赢互惠的开放式医疗创新生态。结语自1992年创立至今，康哲药业顺延行业发展脉络，以前瞻性视野成功推动了三次意义重大的战略转型。公司起步于进口原研药品的代理，逐步发展至控制原研/独家成熟产品权利，再到实现了全面创新转型，每一步都踏在产业发展迭代的节奏中。征程万里风正劲，康哲药业目标如炬，不断垒筑发展厚度，构建穿越周期的韧性。如今，随着国采对公司业绩的影响逐步释放，康哲药业已焕然一新，在拥抱阶段性创新成果的同时，以更充分的准备去迎接未来更长远、更健康的发展。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化业务竞争力，并将皮肤医美、眼科业务独立运营，培育专科小领域的大龙头，提升专科规模效率。同时业务版图拓展至东南亚市场，着力成为全球药企进军东南亚市场的“桥头堡”，助力康哲药业高质量持续健康发展。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及本集团的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。本集团并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，本集团对该等第三方声明及预测不承担责任。 Copyright 2024 亚太商讯 via SeaPRwire.com.

BRISBANE, AUS, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO FSI ANZ 2024 invites cybersecurity professionals in the Financial Services Industry to join this free virtual event designed to inspire and share intelligence. The online gathering will cover everything from cyber strategy, risk management, governance, program and incident management, leadership, to enabling business growth.CISO FSI ANZ offers a unique opportunity to expand your knowledge and find ways to avoid cyber threats in the FSI industry. Benchmark your strategies with peers and learn how to get buy-in and collaboration in your projects across the board.Key topics include:Strategies to advance your company’s cyber security maturity modelsHow to align cyber risk management with the company's goalsComplying with APRA regulations in Australia and MBIE in New ZealandThe impacts of the privacy act reform in information securitySuccessful practices to mitigate the increase of third-party risksBridging the talent gap by investing in culture, education and trainingNavigating the “AI high” by leveraging its benefits while minimising its risksCISO FSI ANZ is an essential online event for those looking to advance their knowledge and network within the cybersecurity community. Join us on 12 September 2024 at 10 AM AEDT or 12 PM NZT.It’s free! Register now: https://bit.ly/4dpyOUYVisit website: https://ciso-fsi-anz.coriniumintelligence.com/About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

CANBERA, AUSTRALIA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO Canberra invites cyber security professionals to explore the critical role of public sector cyber security in protecting the public and driving transformative leadership strategies for delivering the 2023-2030 Australian Cyber Security Strategy.The tech demo exhibition will showcase cutting-edge services and innovations driving change in the cybersecurity landscape. InfoSec leaders will share their strategic insights in no-nonsense talks, providing valuable substance over empty rhetoric.Key themes include:STRENGTH IN UNITY: Building robust shields against cyber threats by navigating the 2023-2030 Australian Cyber Security Strategy to be the most secured nation.AWARENESS, EMPOWERMENT, & COORDINATION: Maturing cyber security culture through collective responsibility and collaborative efforts for enhanced resilience.PROACTIVE GRC MANAGEMENT: Integrating Zero Trust and evaluating risks in supply chains, data and AI to empower decision making at the pace of innovation.MODERNISING THREAT DETECTION & RESPONSE: Embracing cutting-edge technologies and strategies to advance security, integrity and resilience capabilities.CISO Canberra 2024 is an essential event for those looking to advance their knowledge and network within the cybersecurity community. Join us at the Canberra Rex Hotel on 14 November 2024 for an event that promises to inspire and empower.Use the code ACNNEWS20 for 20% off the ticket price.Register here: https://bit.ly/4dqzPfbVisit website: https://ciso-bris.coriniumintelligence.com/ About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. In the case that all medicines were directly sold by the Company, the turnover was RMB4,287.5 million, representing a decrease of 22.6% compared with 1H 2023, an increase of 8.9% compared with 2H 2023; Among which, the total revenue of non-National VBP exclusive products and innovative products was RMB2,404.7 million, accounting for 56.1% of CMS’s revenue in the case that all medicines were directly sold by the Company. Profit for the period was RMB903.4 million, representing a decrease of 52.8% compared with 1H 2023, a substantial increase of 92.8% compared with 2H 2023.The year 2024, not only marks the first year of the commercialization of CMS’s innovative products, but also a crucial point for the release of National Volume Based Procurement (“National VBP”) impact on its financial performance. Deanxit entered the seventh batch of National VBP in November 2022, Plendil and Ursofalk entered the eighth batch of National VBP in July 2023, and none of the three original drugs were selected, which had a negative impact on the Company’s business performance. In 1H 2024, the Company’s overall performance showed a growth trend compared with 2H 2023, indicating that CMS has basically digested the impact of National VBP and successfully entered the "New Product Era" where non-national VBP exclusive products and innovative products drive its growth.With the approval for marketing of LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) in June and METOJECT (Methotrexate Injection)’s additional indication of active rheumatoid arthritis (RA) in adults in July this year, CMS's innovative drug portfolio in the commercialization stage has expanded into 5 products (including 6 indications); simultaneously with a rich and differentiated innovative pipeline reserve. Gathering the power of innovation and riding the momentum of development, CMS is comprehensively shaping new drivers for development with a healthier product structure, further opening up a new cycle of quality development.The "Collaborative and In-house" dual-engine R&D model drives the simultaneous improvement in quantity and quality of the pipeline, accelerating the transformation of innovative biotechnologyA profound innovative drug R&D pipeline is an important driving force for the long-term development of CMS. The Company adheres to the purpose of innovation for meeting the unmet clinical needs and solving the difficulties of patient medication, and promotes innovation development through a two-wheel drive of “Collaborative R&D and In-house R&D”, continuously deploying FIC (first-in-class) and BIC (best-in-class) innovative products, and enhancing the capabilities and efficiency of research and clinical development to achieve a rapid transformation of scientific outcomes into social and commercial values.As of now, CMS's innovative product portfolio approved for marketing in China has been expanded into 5 products (including 6 indications), among which, 4 innovative drugs (VALTOCO, ILUMETRI, METOJECT - psoriasis indication, VELPHORO) have been included in the National Reimbursement Drug List (NRDL) and entered large-scale clinical application; also, CMS newly added LUMEBLUE and METOJECT (RA), for being approved for marketing in China recently.CMS has also steadily advanced the clinical development of innovative products. Currently, Desidustat Tablets is under NDA review in China; Also, a total of about 10 projects have been prepared/launched for their registrational clinical trials, mainly randomized controlled trials (RCT).At the same time, the Company had continued to strengthen basic research and independent innovation capabilities, and successfully promoted more than 10 in-house R&D projects, among which, three innovative drugs (VEGFA/ANG2 Tetravalent Bispecific Antibody, Highly Selective TYK2 Inhibitor CMS-D001 Tablets, and GnRH Receptor Antagonist CMS-D002 Capsules) have entered the clinical development stage.In addition, the Company’s innovative pipeline has continued to expand. CMS Skinhealth collaborated with Incyte once again, and has obtained exclusive license to research, develop, register and commercialize povorcitinib, a selective oral small-molecule JAK1 inhibitor, in countries/territories including Mainland China, Hong Kong, Macau, Taiwan Region and 11 Southeast Asian countries. This further enriched the product portfolio of CMS Skinhealth in the treatment of vitiligo and other immune-mediated dermatology diseases.Subsequently, CMS will continue to produce innovative products with higher efficiency and more controllable costs every year, accelerating the release of innovative value and embracing quality and sustainable performance growth through a healthy product structure dominated by non-National VBP exclusive products and innovative products.Successful commercialization system releases the clinical value of innovative products in an efficient and collaborative mannerAfter 32 years of deep cultivation in specialty therapeutical fields, successful commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, it has achieved in-depth development of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology, and ophthalmology, and expanded its boundaries in related fields. Additionally, the Company established a highly qualified, professional promotion team with strong execution, as well as extensive channel and resource coverage, which has laid a solid foundation for the rapid market entry and brand building of its innovative products.Four innovative drugs of CMS have entered large-scale clinical applications, covering various disease fields such as central nervous system, dermatology, nephrology, and gastroenterology, and developed synergistically with the existing marketed products in promotion team and channels. Meanwhile, leveraging on the opportunity of being included in the NRDL, CMS is advancing hospital development, brand building, real world studies and medically-driven academic promotion. CMS is improving patients’ accessibility to innovative drugs with the help of patient aid and disease knowledge popularization programs, promoting the release of products’ clinical value.The Dermatology and Medical Aesthetic Business "CMS Skinhealth" regards dermatology prescription products as its core, and extends to light medical aesthetic products and dermatology-grade skincare products, continuously improving the construction of a full life-cycle skin-health management platform covering dermatological treatment, skincare, and medical aesthetics through internal development and external collaboration. In terms of clinical development of dermatology prescription drugs, CMS has completed the Pivotal Real World Study for ruxolibinib cream in vitiligo, and is advancing the registration application process in Mainland China. At the same time, it has continuously complemented the regenerative light medical aesthetic portfolio, among which the China’s medical device registration application of the Poly-L-lactic Acid Microparticle Filler Injection has been accepted by the NMPA during the Reporting Period; and the Company has newly obtained exclusive licenses of three regenerative light medical aesthetic products (Polycaprolactone Microsphere Gel for Injection, Calcium Hydroxylapatite Microsphere Gel for Injection, and Decellularized Extracellular Matrix Implant), which are currently under the registrational clinical trial stage in China.The results announcement shows that, as of the end of June, the promotion network of CMS has covered over 55,000 hospitals and medical institutions, and approximately 280 thousand retail pharmacies in China.Leveraging the accumulated advantages in cardio-cerebrovascular, gastroenterology, central nervous system, nephrology, ophthalmology, dermatology and other specialty therapeutical fields, CMS steadily releases the scale effect of its specialty businesses, and builds high competition barriers, creating broad commercial potential for its innovative products and exclusive products.Drawing up the internationalization layout to gather momentum for the incremental marketIntegrating the advantageous resources of the Company, its Southeast Asia business “Rxilient Health”, shares and expands the successful experience of CMS gained from the China market, as well as global quality products and innovative technological resources, into the Southeast Asia market. This accelerates the improvement of the platform integrating “R&D, manufacture, and commercialization” of the Southeast Asia business, empowering Chinese and global pharmaceutical companies to implement the “overseas development” strategy, and also opening up a larger space for incremental development opportunities for CMS.As of the end of June, Rxilient Health has established a competitive product portfolio with more than ten differentiated products, covering therapeutic areas such as oncology, central nervous system, autoimmune, dermatology, and ophthalmology, etc. Rxilient Health is accelerating the relevant work on the market registration processes in Southeast Asian countries for innovative pipeline products, such as ruxolitinib cream, Methylthioninium Chloride Enteric-coated Sustained-release Tablets, and Diazepam Nasal Spray, etc. Furthermore, Rxilient Health collaborated with Junshi Biosciences to promote the registration process of toripalimab (anti-PD-1 monoclonal antibody) in multiple countries in Southeast Asia, aiming to benefit local cancer patients as soon as possible.In December last year, the Company and Rxilient Health joined hands with Pharmaron and other partners to complete the purchase of the Singapore manufacturing plant. This year, all relevant parties have been orderly advancing a series of work for the Singapore manufacturing plant, including equipment testing, quality verification, and production quality system certification, etc., so as to accelerate the CDMO business development, and to optimize the Company’s overseas supply chain and manufacturing capabilities. The business layout will further facilitate more inter-industry cooperation between CMS and global partners in the future, thus jointly building a win-win medical innovation ecosystem with mutual benefits.ConclusionSince its establishment in 1992, CMS has followed the development pattern of the industry and has promoted three significant strategic transformations successfully with a forward-looking vision. The Company started as an agent of imported original drugs, gradually developed to control the rights of original/exclusive products, and then achieved a comprehensive innovative transformation. Each step of the transformation is in sync with the industry development trends. CMS steadily aims towards the ultimate goal, and constantly builds up its strength and resilience to persist through the industry development cycle. With the gradual release of the impact of national VBP on its financial performance, CMS has been transforming into a brand-new company. While embracing the innovation achievements in each stage, CMS is fully prepared for a sustainable and healthier development in the future.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.